Revolutionary treatment for psoriasis

January 11, 2013, The Research Council of Norway

Three per cent of the world's population suffer from the skin condition known as psoriasis. A Norwegian research-based company is close to developing a treatment that could help millions. The research may also prove beneficial in the treatment of other illnesses.

The psoriasis treatment consists of a compound which, when applied to the skin, is absorbed by much more naturally than most other ointments. It contains a synthesised molecule based on the fatty acid docosahexaenoic acid () which may prove effective in inhibiting associated with psoriasis.

Clinical trials soon underway

Avexxin, a Trondheim-based company, is to begin clinical testing of the ointment in early 2013. If the results are positive, Avexxin may find itself on the cusp of an international breakthrough.

Successful tests of the psoriasis compound could also give an important boost to the pursuit of more comprehensive clinical trials to determine whether the technology can be applied to other such as rheumatoid arthritis and nephritis, an inflammation in the kidneys.

Combining clinical phases 1 and 2A

Clinical trials often extend over a long period of time. The treatment must first be tested for toxicity on healthy volunteers. Subsequent trials must be carried out on real patients to ensure that the treatment has the desired effect. With an ointment such as this, which is to be applied externally, it is possible to combine trial phases 1 and 2A.

"This enables us to save a lot of time," explains Professor Berit Johansen of the Norwegian University of Science and Technology (NTNU). Dr Johansen has been studying the mechanisms behind inflammatory disease since the end of the 1980s. She launched the company, Avexxin, in 2005.

Potential for treating other conditions

Two Avexxin projects have received funding under the programme for User-driven Research-based Innovation (BIA) at the Research Council of Norway:

  • Development of mechanism based, novel anti-inflammatory compounds (2006-2009)
  • Expanding drug pipeline in Avexxin - adopting new chemistry (2009-2012)
"We have been lucky in obtaining private funding that supports our main focus – the development of a medicine for treating psoriasis," Dr Johansen explains.

"The financial support we have received from the Research Council has been critical to our research and has enabled us to develop several molecules to treat other inflammatory conditions with the same target as psoriasis. These molecules could prove effective in treating and nephritis," Dr Johansen states.

"When we carried out tests in summer 2012 to see whether one of the new molecules might have any effect on arthritis in animals, the results were extremely encouraging."

Substantial international attention

"Our most recent results are especially important now that we have begun negotiating with international pharmaceutical companies towards potential agreements," Berit Johansen says. Three leading pharmaceutical companies are currently courting the Norwegian team.

If the decisive clinical trial proves a success Dr Johansen and her colleagues will enter into discussions on licensing their patent to one of these companies. This will be the company that undertakes the final clinical trials.

Avexxin was recently nominated as one of the world's Top 10 Autoimmune/Anti-Inflammatory companies to watch.

Explore further: Treating psoriasis to prevent heart attacks and strokes

Related Stories

Treating psoriasis to prevent heart attacks and strokes

March 16, 2012
A clinical study co-led by the Montreal Heart Institute and Innovaderm Research Inc., which was presented today at the annual meeting of the American Academy of Dermatology, shows that a new treatment for psoriasis could ...

Immune cells can be altered to help fight inflammatory diseases, research finds

October 11, 2012
(Medical Xpress)—A fundamental mechanism controlling cells of the human immune system could be key to helping fight inflammatory diseases such as rheumatoid arthritis and psoriasis, new research at the University of Dundee ...

New medication, surgery may offer relief for patients with psoriatic arthritis

January 18, 2012
Medications or biologic agents that target T-cells, white blood cells involved in the body's immune system, appear to offer significant benefit to patients suffering from psoriatic arthritis (PsA), a type of arthritis that ...

Psoriasis increases risk of diabetes: study

June 18, 2012
Psoriasis is an independent risk for Type 2 Diabetes, according to a new study by researchers with the Perelman School of Medicine at the University of Pennsylvania, with the greatest risk seen in patients with severe psoriasis. ...

Recommended for you

Study ends debate over role of steroids in treating septic shock

January 19, 2018
The results from the largest ever study of septic shock could improve treatment for critically ill patients and save health systems worldwide hundreds of millions of dollars each year.

New approach could help curtail hospitalizations due to influenza infection

January 18, 2018
More than 700,000 Americans were hospitalized due to illnesses associated with the seasonal flu during the 2014-15 flu season, according to federal estimates. A radical new approach to vaccine development at UCLA may help ...

Flu may be spread just by breathing, new study shows; coughing and sneezing not required

January 18, 2018
It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from ...

Zika virus damages placenta, which may explain malformed babies

January 18, 2018
Though the Zika virus is widely known for a recent outbreak that caused children to be born with microencephaly, or having a small head, and other malformations, scientists have struggled to explain how the virus affects ...

Certain flu virus mutations may compensate for fitness costs of other mutations

January 18, 2018
Seasonal flu viruses continually undergo mutations that help them evade the human immune system, but some of these mutations can reduce a virus's potency. According to new research published in PLOS Pathogens, certain mutations ...

Study reveals how MRSA infection compromises lymphatic function

January 17, 2018
Infections of the skin or other soft tissues with the hard-to-treat MRSA (methicillin-resistant Staphylococcus aureus) bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.